CYTK Cytokinetics
- 47.370
- -1.140-2.35%
- 47.370
- 0.0000.00%
Cytokinetics News
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BofA Securities Maintains Cytokinetics(CYTK.US) With Hold Rating, Maintains Target Price $62
Express News | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Investors Push Cytokinetics (NASDAQ:CYTK) 3.7% Lower This Week, Company's Increasing Losses Might Be to Blame
S&P 500 Futures Drop In Premarket Trading; Sportradar Group, Cytokinetics Lead
Biggest Stock Movers Tuesday: X, CYTK, and More
Cytokinetics Says European Regulator Validated Its Application for Cardiomyopathy Drug Candidate
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating
Express News | Cytokinetics Inc - FDA Sets Pdufa Target Action Date for Aficamten Nda as Sept 26, 2025
Express News | Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy
Truist Financial Sticks to Their Buy Rating for Cytokinetics (CYTK)
Why Cytokinetics Stock Was a Nearly 5% Winner Today
H.C. Wainwright Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $120
Cytokinetics Price Target Maintained With a $120.00/Share by HC Wainwright & Co.
Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China
Express News | Cytokinetics Inc - Eligible for up to $150 Million in Milestone Payments From Sanofi
Express News | Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK)
RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $82
Cytokinetics Is Maintained at Outperform by RBC Capital
No Data